What is the optimal therapy for Crohn’s disease: step-up or top-down?

Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial

(2009) Jean-Frédéric Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis

(2009) Laurent Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab for the treatment of fistulas in patients with Crohn's disease

(2009) J-F Colombel et al.   GUT

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: Update

(2009) Ann Corken Mackey et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials

(2008) Laurent Peyrin–Biroulet et al.   Clinical Gastroenterology and Hepatology

Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse

(2008) Xavier Treton et al.   Clinical Gastroenterology and Hepatology

p16INK4a Is a β-Catenin Target Gene and Indicates Low Survival in Human Colorectal Tumors

(2008) Stella Wassermann et al.   GASTROENTEROLOGY

Hepatosplenic T cell lymphoma in inflammatory bowel disease

(2008) M. Shale et al.   GUT

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

The comeback kid: TYSABRI now FDA approved for Crohn disease

(2008) Karen Honey   JOURNAL OF CLINICAL INVESTIGATION

Initial combination therapy in early Crohn's disease

(2008) William J Sandborn   LANCET

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET